返回 
加入收藏
药物经济学评价中“免费仍不经济”类结果的原因分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 药物经济学评价中“免费仍不经济”类结果的原因分析 |
| TITLE： | Cause Analysis of “Not Cost-effective at a Zero Price ”Results in Pharmacoeconomic Evaluation |
| 摘要： | 目的：为今后开展相关药物经济学评价提供参考和借鉴。方法：通过4个药物经济学评价典型案例展示可能出现“免费仍不经济”的特殊情况，定义“净价值”的概念来协助进行理论分析，并归纳导致这种情况的可能原因。结果与结论：目标药物之外的背景治疗成本过高、患者存活期间生命质量过低、增量成本-效果比的意愿支付阈值过低、延长生存期间风险事件的成本过高或者健康损失过高以及对照方案价格过低等都有可能影响经济性评价的结果，甚至出现“免费仍不经济”的药物经济学评价困境。药物经济学评价讨论的是干预方案的经济性而非药物的经济性问题，对于存在多种原因所导致的不经济的结果，需要客观看待；从理论上来说，药物经济学评价中应当将所有“相关”和“不相关”的成本都纳入计算范畴；药物经济学主要解决的是若干治疗方案之间“性价比”问题，而医疗卫生领域常常还需要面对伦理和公平性等问题，故研究者可能需要跳出药物经济学分析的框架，从更高、更广的角度进行深入讨论。 |
| ABSTRACT： | OBJECTIVE：To pr ovide reference for the future pharmacoeconomic evaluation. METHODS ：Four typical cases of pharmacoeconomic evaluation showed the special situation that “not cost-effective at a zero price ”，defined the concept of “net value”to assist in theoretical analysis ，and summarized the possible causes of this situation . RESULTS & CONCLUSIONS ：The system（ATPS）：an overview and advances in its applica background treatment cost other than the target drug was too high ，the patient ’s quality of life during survival was too low ，the threshold of willingness to pay of incremental cost-effectiveness ratio was too low ，the cost of risk events during extended survival was too high or the health loss was too high ，and the price of the control scheme was too low ，which might affect the results of economic evaluation ，and even le d to the dilemma of pharmacoeconomic evaluation of “not cost-effective at a zero price ”. Pharmacoeconomic evaluation discusses the economy of intervention programs rather than the economy of drugs. The uneconomic results caused by various reasons need to be treated objectively ；theoretically，all“relevant”and“irrelevant”costs should be included in the calculation category in pharmacoeconomic evaluation ；pharmacoeconomics mainly solves the problem of “cost performance”comparison among several treatment schemes ，and the medical and health field often needs to face problems such as ethics and fairness. Therefore ，researchers may need to jump out of the framework of pharmacoeconomics analysis and conduct in-depth discussion from a higher and broader perspective. |
| 期刊： | 2021年第32卷第18期 |
| 作者： | 管欣，王璐颖，李洪超 |
| AUTHORS： | GUAN Xin，WANG Luying ，LI Hongchao |
| 关键字： | 药物经济学；免费仍不经济；背景治疗；成本；原因分析 |
| KEYWORDS： | Pharmacoeconomics；Not cost-effective at a zero price ；Background therapy ；Cost；Cause analysis |
| 阅读数： | 395 次 |
| 本月下载数： | 20 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
